Giovanni Cincilla, PhD, obtained his doctoral degree in cheminformatics from the Institute for Research in Biomedicine (IRB) and the University of Barcelona, Spain, in 2010. For four months during his doctoral studies, he worked in the laboratory of Prof. Willett, an expert in the cheminformatics field. He then gained postdoctoral experience at GRIB-IMIM (Research Programme on Biomedical Informatics) in Spain, where he participated in a European Union-funded project for the in silico prediction of toxicity before starting his career in the pharmaceutical industry. After about four years and 15 diverse drug discovery projects in collaboration with different pharmaceutical companies, he co-founded Molomics Biotech, a company dedicated to the design of safer and more effective drug candidates by means of artificial intelligence (AI). As chief scientific officer of Molomics, he develops new AI approaches and manages the company's drug discovery programs in Parkinson's disease.